{"title":"Allergic Bronchopulmonary Aspergillosis: A Clinical Evaluation of 15 Patients and Successful Omalizumab Treatment of Five Patients","authors":"D. Ünal","doi":"10.21911/AAI.476","DOIUrl":null,"url":null,"abstract":"Objective: Allergic bronchopulmonary aspergillosis (ABPA) is an immunological lung disease caused by hypersensitivity reactions to Aspergillus antigen. Studies on the efficacy of omalizumab treatment in patients diagnosed with ABPA are limited to case reports and small series. Our aim was to evaluate the effectiveness of omalizumab treatment in ABPA in addition to clinical, radiological and serological characteristics these patients. Materials and Methods: This study is a prospective observational one. It included clinical review of 15 patients diagnosed with ABPA and the successful omalizumab treatment of 5 of these patients. Patients receiving omalizumab therapy were assessed at baseline, after 1 year and 3 years of starting treatment. Results: 15 patients (9 males, 6 females, mean age: 48.26 ± 9.92 years) diagnosed as ABPA were enrolled. One patient had received antituberculosis medications prior to diagnosis. The mean serum total IgE level was 1665 ± 909 IU/mL. The most common finding in thorax high-resolution computed tomography was central bronchiectasis. Omalizumab treatment was started in five patients with asthma and ABPA who have failed to respond to Global Initiative for Asthma step 4 treatment. Conclusion: ABPA should be considered in patients with uncontrolled or severe asthma, despite appropriate asthmatic treatment. Recognizing ABPA is important, because early diagnosis can delay the development or prevent the bronchiectasis that causes fibrotic lung disease. Omalizumab is an effective therapy option in patients with asthma and ABPA who fail to respond to Global Initiative for Asthma step 4 treatment.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Astim Allerji Immunoloji","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21911/AAI.476","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 3
Abstract
Objective: Allergic bronchopulmonary aspergillosis (ABPA) is an immunological lung disease caused by hypersensitivity reactions to Aspergillus antigen. Studies on the efficacy of omalizumab treatment in patients diagnosed with ABPA are limited to case reports and small series. Our aim was to evaluate the effectiveness of omalizumab treatment in ABPA in addition to clinical, radiological and serological characteristics these patients. Materials and Methods: This study is a prospective observational one. It included clinical review of 15 patients diagnosed with ABPA and the successful omalizumab treatment of 5 of these patients. Patients receiving omalizumab therapy were assessed at baseline, after 1 year and 3 years of starting treatment. Results: 15 patients (9 males, 6 females, mean age: 48.26 ± 9.92 years) diagnosed as ABPA were enrolled. One patient had received antituberculosis medications prior to diagnosis. The mean serum total IgE level was 1665 ± 909 IU/mL. The most common finding in thorax high-resolution computed tomography was central bronchiectasis. Omalizumab treatment was started in five patients with asthma and ABPA who have failed to respond to Global Initiative for Asthma step 4 treatment. Conclusion: ABPA should be considered in patients with uncontrolled or severe asthma, despite appropriate asthmatic treatment. Recognizing ABPA is important, because early diagnosis can delay the development or prevent the bronchiectasis that causes fibrotic lung disease. Omalizumab is an effective therapy option in patients with asthma and ABPA who fail to respond to Global Initiative for Asthma step 4 treatment.
期刊介绍:
Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.